Long-term molecular remission in Philadelphia-positive acute lymphoblastic leukemia elderly patient after dasatinib discontinuation

Leuk Lymphoma. 2016 Oct;57(10):2445-7. doi: 10.3109/10428194.2016.1140163. Epub 2016 Feb 15.

Authors

Ernesto Vigna¹, Massimo Gentile¹, Giovanna Giagnuolo¹, Anna Grazia Recchia^{1

2}, Sabrina Bossio^{1

2}, Laura De Stefano^{1

2}, Rosellina Morelli³, Fortunato Morabito^{1

2}

Affiliations

¹ a Hematology Unit, Department of Onco-Hematology , AO Of Cosenza , Cosenza , Italy ;
² b Biotechnology Research Unit, Aprigliano, AO/ASP Of Cosenza , Cosenza , Italy ;
³ c Nuclear Medicine Unit, Department of Onco-Hematology , AO Of Cosenza , Cosenza , Italy.

PMID: 26879289
DOI: 10.3109/10428194.2016.1140163

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Age Factors
Aged
Dasatinib
Female
Humans
Philadelphia Chromosome*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Remission Induction*
Time Factors
Treatment Outcome
Withholding Treatment

Substances

Dasatinib